INVESTIGATION OF LEVEL OF SERUM INTERLEUKİN 17 IN AGE-RELATED MACULAR DEGENERATİON
Sabuncuoglu Serefeddin Health Sciences · 2022
DOI: 10.55895/sshs.1145995 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sabuncuoglu Serefeddin Health Sciences, 2022. Verfasst von Hatice Türker Aslan und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Age-related macular degeneration (AMD) is a non-recyclable visual disorder among elderly people worldwide and AMD is one of the leading causes of blindness. Former studies, interleukins were found to be effective in patients with AMD. This study’s object, the relationship of serum interleukin 17 with age-related macular degeneration was evaluated. Interleukin 17 levels were measured by ELISA method using the blood sera of 100 patients diagnosed with age-related macular degeneration and 100 healthy individuals in the control group. Acording to the results of the study, the differences between the patient and control groups of interleukin 17 levels was found statistically significant (p:0,001; p > 0,05). It was found that gender difference in patients did not affect interleukin 17 levels (p=0,649; p > 0,05). In the study, there was a significant relationship between age-related macular degeneration and serum interleukin 17.
Zitieren
APA
Aslan, H. T., & Ateş, Ö. (2022). INVESTIGATION OF LEVEL OF SERUM INTERLEUKİN 17 IN AGE-RELATED MACULAR DEGENERATİON. Sabuncuoglu Serefeddin Health Sciences. https://doi.org/10.55895/sshs.1145995
Vancouver
Aslan HT, Ateş Ö. INVESTIGATION OF LEVEL OF SERUM INTERLEUKİN 17 IN AGE-RELATED MACULAR DEGENERATİON. Sabuncuoglu Serefeddin Health Sciences. 2022. doi:10.55895/sshs.1145995
BibTeX
@article{Aslan2022,
author = {Aslan, Hatice Türker and Ateş, Ömer},
title = {INVESTIGATION OF LEVEL OF SERUM INTERLEUKİN 17 IN AGE-RELATED MACULAR DEGENERATİON},
journal = {Sabuncuoglu Serefeddin Health Sciences},
year = {2022},
doi = {10.55895/sshs.1145995}
}
EUVIMED